Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pregabalin + oxcarbazepine is a combination of two antiepileptic (anticonvulsant) drugs used together primarily for the management of partial-onset seizures and potentially for neuropathic pain. Pregabalin is a structural analogue of gamma-aminobutyric acid (GABA) that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing neurotransmitter release and neuronal excitability. Oxcarbazepine is a prodrug that is converted to its active metabolite, which blocks voltage-sensitive sodium channels, stabilizing hyperexcited neural membranes and inhibiting repetitive neuronal firing. The combination may provide additive anticonvulsant effects; preclinical studies show additive or synergistic interactions in seizure models without significant acute adverse effects on motor coordination or memory. However, combined use can increase risks of central nervous system depression such as dizziness, drowsiness, confusion, and impaired concentration[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pregabalin + oxcarbazepine.